Document is current
Any future updates will be listed below
-
Authors
Tang, Ming
Abbas, Hussein A. https://orcid.org/0000-0003-2946-3562
Negrao, Marcelo V. https://orcid.org/0000-0001-8938-6699
Ramineni, Maheshwari
Hu, Xin
Hubert, Shawna Marie https://orcid.org/0000-0002-7907-9609
Fujimoto, Junya
Reuben, Alexandre https://orcid.org/0000-0003-4510-0382
Varghese, Susan
Zhang, Jianhua https://orcid.org/0000-0001-5412-9860
Li, Jun
Chow, Chi-Wan
Mao, Xizeng
Song, Xingzhi
Lee, Won-Chul
Wu, Jia https://orcid.org/0000-0001-8392-8338
Little, Latasha
Gumbs, Curtis
Behrens, Carmen
Moran, Cesar https://orcid.org/0000-0003-1158-5713
Weissferdt, Annikka
Lee, J. Jack https://orcid.org/0000-0001-5469-9214
Sepesi, Boris
Swisher, Stephen https://orcid.org/0000-0002-3080-1920
Cheng, Chao https://orcid.org/0000-0002-5002-3417
Kurie, Jonathan https://orcid.org/0000-0002-1472-8719
Gibbons, Don https://orcid.org/0000-0003-2362-3094
Heymach, John V. https://orcid.org/0000-0001-9068-8942
Wistuba, Ignacio I.
Futreal, P. Andrew https://orcid.org/0000-0001-8663-2671
Kalhor, Neda https://orcid.org/0000-0001-6891-6435
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
- License Information
-
More Information
Article History
Received: 14 January 2021
Accepted: 16 November 2021
First Online: 6 December 2021
Change Date: 8 April 2022
Change Type: Update
Change Details: In the PDF version of this article, the equal contribution of Ming Tang and Hussein A. Abbas affiliation was incorrectly denoted as 14. The correction number is 11. The PDF has now been corrected.
Competing interests
: Jianjun Zhang reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent outside the submitted work. J. V. H. reports research funding from AstraZeneca, GlaxoSmithKline, and Spectrum; consultant fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, EMD Serono, Foundation Medicine, Hengrui Therapeutics, Genentech, GSK, Guardant Health, Eli Lilly, Merck, Novartis, Pfizer, Roche, Sanofi, Seattle Genetics, Spectrum, and Takeda; licensing fees from Spectrum. B. S. reports consultant fees from BMS. M. V. N. reports research funding from Mirati, Novartis, Checkmate, Ziopharm, AstraZeneca, Pfizer, and Genentech; consultant fees from Mirati, Merck/MSD. The other authors declare neither financial nor non-financial interests in the submitted work.
